Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | IP6K1 | Q92551 | 2/20 | 0.52 |
| ▸ | GRK6 | P43250 | 1/20 | 0.48 |
| ▸ | CCNE2 | O96020 | 3/20 | 0.48 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.48 |
| ▸ | CDK2 | P24941 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 3/20 | 0.45 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.44 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.44 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17815679 | 0.88 | MAPT (0.67) | MAPTCCNE2CCNE1CDK2TDP1 | |
| SCHEMBL17815578 | 0.85 | MAPT (0.53) | MAPTIP6K1CCNE2CCNE1CDK2 | |
| SCHEMBL17802550 | 0.84 | MAPT (0.53) | MAPTIP6K1CCNE2CCNE1CDK2 | |
| SCHEMBL17815683 | 0.84 | MAPT (0.48) | MAPTIP6K1CCNE2CCNE1CDK2 | |
| SCHEMBL8826162 | 0.77 | APP (0.56) | MAPTCCNE2CCNE1CDK2TDP1 | |
| SCHEMBL3108534 | 0.77 | CCNE2 (0.61) | MAPTCCNE2CCNE1CDK2TDP1 | |
| SCHEMBL17802610 | 0.76 | MAPT (0.47) | MAPTCCNE2CCNE1CDK2TDP1 | |
| SCHEMBL17815610 | 0.76 | IP6K1 (0.48) | IP6K1CNR2 | |
| SCHEMBL723440 | 0.75 | CDK1 (0.59) | MAPT | |
| SCHEMBL16146205 | 0.75 | PRMT1 (0.41) | MAPTMAP2K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10414768-B2 | Compounds for treating cystic fibrosis | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2019-09-17 | — | — | US | disclosed |
| US-10414768-B2 | Compounds for treating cystic fibrosis | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2019-09-17 | — | — | US | disclosed |
| US-20170362239-A1 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6 (UPMC) (FR) | 2017-12-21 | — | — | US | disclosed |
| US-20170362239-A1 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6 (UPMC) (FR) | 2017-12-21 | — | — | US | disclosed |
| US-20170362239-A1 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6 (UPMC) (FR) | 2017-12-21 | — | — | US | disclosed |
| WO-2016087665-A2 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2016-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10414768-B2 | Compounds for treating cystic fibrosis | CFTR, ABCB11, SLC26A4 | MAPT 4816/4885IP6K1 2909/4885GRK6 4348/4885 |
| US-20170362239-A1 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | CFTR, ABCB11, SLC26A4 | MAPT 4816/4885IP6K1 2909/4885GRK6 4348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.